The pharmaceutical sector is one of the few industries that has been relatively less impacted amidst the COVID-19 pandemic.
Outsourcing provides a platform for establishing strategic collaborations, which eventually helps players to augment their expertise in this domain, through access to lucrative and innovative cost cutting peptide synthesis technologies offered by CMOs.
An informed capability assessment of different geographies, such as North America, Europe and Asia Pacific, is based on a variety of relevant parameters, such as number of CMOs, number of clinical sites, number of completed / active / planned clinical trials, number of patients enrolled, number of manufacturing facilities, number of CMOs offering manufacturing for API / FDF, number of CMOs having capabilities for clinical / commercial manufacturing, current demand for peptide therapeutics and installed manufacturing capacity in a particular region. Where, North America emerged as the most prominent region as per the above-mentioned parameters. It is worth highlighting that across all the regions, the peptide manufacturing facilities are capable of providing manufacturing services at the clinical scale.
Given the growing preference for outsourcing in the pharmaceutical industry, it is imperative for stakeholders to be able to draw a distinction between making a product (insourcing) or buying it from a third-party supplier (outsourcing).
The annual, global demand for therapeutic peptide APIs is estimated to be 2,145 kg in 2020, and this value is projected to reach about 3,800 kg by 2025, growing at a CAGR of 10%.
The number and geographical distribution of clinical trials are important indicators of both the therapeutic viability and future potential of innovative pharmacological interventions.
During our research, we came across several partnerships and collaborations that have been inked, during the period 2014-2019, between various stakeholders involved in the peptide therapeutics contract manufacturing domain.
The introduction of insulin therapy in the 1920s, for the treatment of diabetes, marked the beginning of the therapeutic use of peptides.